BPC-157

Evidence Anchor

BioHarmony 7.5/10

BPC-157 is a 7.5 / 10 fit for adults considering an investigational recovery peptide after basic rehab, sleep, protein, and load management are already handled, not a proven human longevity or injury cure. The cleanest evidence anchors are [Vasireddi 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/), which reviewed 36 sports-medicine studies and found 35 were preclinical plus one clinical study, and [Gwyer 2019](https://pubmed.ncbi.nlm.nih.gov/30915550/), which supports the tendon, ligament, and muscle repair direction in animal work. [Lee 2025](https://pubmed.ncbi.nlm.nih.gov/40131143/) adds useful context: reported a tiny two-person IV safety pilot that cannot answer efficacy. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, BPC-157 belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol. ✅ Best for: Healthy adults with acute soft-tissue injuries, stubborn tendon or ligament recovery, muscle strains, wound-healing goals, or post-surgical recovery questions where standard care is already handled and a clinician is not concerned about angiogenesis or clotting risk. BPC-157 is most defensible as a short, scoped repair experiment layered on top of rehab, sleep, adequate protein, load management, and diagnostic clarity. Oral arginine salt is the cleaner choice for gut-focused self-experimentation, while subcutaneous acetate is the common community route for local injury protocols. Non-tested athletes and experienced peptide users should still verify product purity. ❌ Avoid if: You have current cancer, a cancer history that makes angiogenesis concerning, pre-malignant lesions, proliferative retinopathy, pregnancy, planned pregnancy, breastfeeding, therapeutic anticoagulation, unexplained pain that has not been diagnosed, or any reason sterile injection technique is unrealistic. Avoid BPC-157 if you compete under WADA rules, because BPC-157 is prohibited under S0 non-approved substances. Also avoid if you need guideline-backed medical care for ulcerative colitis, tendon rupture, neurological injury, chronic pain, or post-surgical complications. BPC-157 may be promising, but it is not standard of care.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.